Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) closed at $27.32 in the last session, up 0.66% from day before closing price of $27.14. In other words, the price has increased by $0.66 from its previous closing price. On the day, 1.81 million shares were traded. RARE stock price reached its highest trading level at $27.53 during the session, while it also had its lowest trading level at $26.85.
Ratios:
We take a closer look at RARE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.24 and its Current Ratio is at 2.40. In the meantime, Its Debt-to-Equity ratio is 6.17 whereas as Long-Term Debt/Eq ratio is at 5.70.
Goldman Upgraded its Neutral to Buy on June 06, 2024, whereas the target price for the stock was revised from $56 to $67.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 20 ’25 when Sanders Corazon (Corsee) D. sold 2,405 shares for $37.39 per share. The transaction valued at 89,923 led to the insider holds 15,344 shares of the business.
CORAZON D. SANDERS bought 2,405 shares of RARE for $89,923 on Jun 20 ’25. On May 05 ’25, another insider, Crombez Eric, who serves as the EVP and Chief Medical Officer of the company, sold 520 shares for $39.24 each. As a result, the insider received 20,405 and left with 71,530 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 2582887424 and an Enterprise Value of 2980708096. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.37 while its Price-to-Book (P/B) ratio in mrq is 17.75. Its current Enterprise Value per Revenue stands at 5.046 whereas that against EBITDA is -6.237.
Stock Price History:
The Beta on a monthly basis for RARE is 0.24, which has changed by -0.45868832 over the last 52 weeks, in comparison to a change of 0.18569505 over the same period for the S&P500. Over the past 52 weeks, RARE has reached a high of $60.37, while it has fallen to a 52-week low of $25.81. The 50-Day Moving Average of the stock is -19.81%, while the 200-Day Moving Average is calculated to be -32.98%.
Shares Statistics:
According to the various share statistics, RARE traded on average about 1.76M shares per day over the past 3-months and 2593280 shares per day over the past 10 days. A total of 93.74M shares are outstanding, with a floating share count of 88.38M. Insiders hold about 6.52% of the company’s shares, while institutions hold 95.93% stake in the company. Shares short for RARE as of 1752537600 were 8801643 with a Short Ratio of 5.00, compared to 1749772800 on 6081072. Therefore, it implies a Short% of Shares Outstanding of 8801643 and a Short% of Float of 9.6499994.
Earnings Estimates
A comprehensive evaluation of Ultragenyx Pharmaceutical Inc (RARE) is underway, with the input of 11.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$1.31, with high estimates of -$1.01 and low estimates of -$1.51.
Analysts are recommending an EPS of between -$4.51 and -$5.78 for the fiscal current year, implying an average EPS of -$5.32. EPS for the following year is -$3.56, with 11.0 analysts recommending between -$0.85 and -$5.88.
Revenue Estimates
According to 18 analysts, the current quarter’s revenue is expected to be $161.37M. It ranges from a high estimate of $170.3M to a low estimate of $148M. As of the current estimate, Ultragenyx Pharmaceutical Inc’s year-ago sales were $147.03MFor the next quarter, 18 analysts are estimating revenue of $164.5M. There is a high estimate of $174.43M for the next quarter, whereas the lowest estimate is $150M.
A total of 20 analysts have provided revenue estimates for RARE’s current fiscal year. The highest revenue estimate was $668.35M, while the lowest revenue estimate was $589M, resulting in an average revenue estimate of $649.53M. In the same quarter a year ago, actual revenue was $560.23MBased on 20 analysts’ estimates, the company’s revenue will be $822.7M in the next fiscal year. The high estimate is $1.02B and the low estimate is $664.4M.
